Major Depressive Disorder Clinical Trials in Orlando, Florida

9 studies are recruiting for major depressive disorder in Orlando, Florida right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)

   A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Major Depressive Disorder - Ascend

   Stage

   Phase 3

   Ages

   18 to 74

   Site

   Clinical Neuroscience Solutions, LLC (Orlando), Orlando, Florida

   Locations

   30 in total

   Run by

   Definium Therapeutics US, Inc.

   See if you can join NCT07592689 on ClinicalTrials.gov

2. Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder

   The goal of this clinical trial is to learn if zelquistinel works to treat depression in adults. It will also learn about the safety of zelquistinel. The main questions it aims to answer are: Does zelquistinel reduce depression scores in participants compared to participants who take a placebo (a l…

   Stage

   Phase 2

   Ages

   18 to 64

   Site

   Clinical Neuroscience Solutions, Inc., Orlando, Florida

   Locations

   34 in total

   Run by

   Syndeio Biosciences, Inc

   See if you can join NCT06547489 on ClinicalTrials.gov

3. A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder

   X-NOVA2 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major Depressive Disorder (MDD)

   Stage

   Phase 3

   Ages

   18 to 74

   Site

   Clinical Neuroscience Solutions, Inc., Orlando, Florida

   Locations

   51 in total

   Run by

   Xenon Pharmaceuticals Inc.

   See if you can join NCT06775379 on ClinicalTrials.gov

4. Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

   This study will evaluate the long-term safety and tolerability of NBI-1065845 as an adjunctive treatment in participants with MDD.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Neurocrine Clinical Site, Orlando, Florida

   Locations

   106 in total

   Run by

   Neurocrine Biosciences

   See if you can join NCT06966401 on ClinicalTrials.gov

5. A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

   The primary objective of this study is to evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in delaying relapse of depressive symptoms (maintenance of effect) in participants with MDD.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Neurocrine Clinical Site, Orlando, Florida

   Locations

   60 in total

   Run by

   Neurocrine Biosciences

   See if you can join NCT07196501 on ClinicalTrials.gov

6. A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder

   Major depressive disorder (MDD; depression) is a mood disorder that causes a continued feeling of sadness and loss of interest. It is a common and serious illness that can cause both emotional and physical symptoms such as feelings of sadness, irritability, not being able to focus on activities, ti…

   Stage

   Phase 2

   Ages

   18 to 65

   Site

   Clinical Neuroscience Solutions - Orlando - East South Street /ID# 277558, Orlando, Florida

   Locations

   33 in total

   Run by

   AbbVie

   See if you can join NCT07276997 on ClinicalTrials.gov

7. Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)

   The goal of this clinical trial is to learn if ABX-002 added to an existing antidepressant treatment will benefit depression symptoms in adults with moderate to severe major depressive disorder who have had an inadequate response to their antidepressant. This is a double-blind, placebo-controlled, …

   Stage

   Phase 2

   Ages

   18 to 65

   Site

   Autobahn Site #102, Orlando, Florida

   Locations

   50 in total

   Run by

   Autobahn Therapeutics, Inc.

   See if you can join NCT06633016 on ClinicalTrials.gov

8. Targeting Network Dysfunction in Apathy of Late-life Depression Using Digital Therapeutics

   The goal of this randomized controlled trial is to evaluate the potential of a customized digital cognitive training intervention to target aspects of brain function in apathy of late-life depression and reduce symptoms of apathy and related cognitive and behavioral deficits. The investigators hypo…

   Stage

   Not phased

   Ages

   60 and older

   Site

   AdventHealth Neuroscience Institute, Orlando, Florida

   Run by

   AdventHealth

   See if you can join NCT05877885 on ClinicalTrials.gov

9. A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms

   This is a randomized, double-blind, active-controlled, multi-center study to evaluate the efficacy of AXS-05, compared to bupropion, in preventing the relapse of depressive symptoms in subjects with major depressive disorder (MDD) who have responded to treatment with AXS-05.

   Stage

   Phase 4

   Ages

   18 to 65

   Site

   Clinical Research Site, Orlando, Florida

   Locations

   40 in total

   Run by

   Axsome Therapeutics, Inc.

   See if you can join NCT06223880 on ClinicalTrials.gov